Clinical Trials

At the Penn Pancreatic Cancer Research Center (PCRC), clinical trials offer access to promising new therapies that may not yet be available through standard treatment. Choosing to participate is a personal decision—and an opportunity to contribute to the advancement of pancreatic cancer care.

Each trial has specific eligibility criteria based on factors such as diagnosis, prior treatments, and overall health. If you’re interested in joining a study, our research team will guide you through a screening process to determine whether a trial is a good fit. Participation may involve additional appointments for labs, imaging, treatment, or follow-up, and the time commitment can vary depending on the study’s design.

If you are uninsured or an international patient, we encourage you to explore financial planning or coverage options prior to contacting our team. Most clinical trials require either insurance or other financial arrangements in place before participation can be considered. Understanding these requirements ahead of time can help ensure a smoother process and avoid delays in care. Our dedicated physicians, nurses, and research coordinators are here to support you. We invite you to speak with your Penn oncologist or contact our Pancreas Nurse Navigator to learn more about whether a clinical trial may be right for you.

Adjuvant

Trial Number

Intervention

Type of Therapy

Description

PI/Contact

UPCC EA2192 (APOLLO)

Olaparib

Adjuvant

Randomized study of olaparib vs placebo for one year following adjuvant chemotherapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2 or PALB2 mutation. Patients must be cancer-free at time of enrollment

Kim Reiss

Neoadjuvant
Trial Number	Intervention	Type of Therapy	Description	PI/Contact

Localized, Resectable
Trial Number	Intervention	Type of Therapy	Description	PI/Contact

Localized, Unresectable
Trial Number	Intervention	Type of Therapy	Description	PI/Contact

Metastatic Trials — First Line (Initial Treatment for Newly Metastatic Diagnosis)

Trial Number

Intervention

Type of Therapy

Description

PI/Contact

UPCC 23222

(Verastem)

Gemcitabine, Paclitaxel, Defactinib, Avutometinib

1^st Line Metastatic

A Phase lb/2a study of gemcitabine and nab-paclitaxel in combination with avutometinib (vS-6766) and defactinib in patients with previously untreated metastatic pancreatic adenocarcinoma

Mark O’Hara, Natallia Izgur

UPCC 07224

(RevMed Subprotocol C [limited slots])

RMC-6236

(RAS-MULTI(ON) Inhibitor)

1^st Line Metastatic

Subprotocol C: RMC-6236 and gemcitabine with nab-paclitaxel in previously untreated metastatic pancreatic adenocarcinoma

Mark O’Hara

Metastatic Trials — Second Line
Trial Number	Intervention	Type of Therapy	Description	PI/Contact
UPCC 23224 (RASolute)		2^nd Line Metastatic	Rasolute 302: A Phase 3, open-label, randomized study of RMC-6236 versus investigator’s choice of standard of care therapy in Patient with previously treated metastatic pancreatic ductal adenocarcinoma	Mark O’Hara
UPCC 18223 (Geistlich)	Gemcitabine, GP-2250 (Metabolic Inhibitor)	2^nd Line Metastatic	A Phase 1 trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of GP-2250 in combination with gemcitabine in subjects with advanced unresectable or metastatic pancreatic adenocarcinoma who have progressed on prior treatment with 5-fluorouacil-based chemotherapy	Mark O’Hara
UPCC 07225 (STELLA)	ART0380 Irinotecan	2^nd Line Metastatic ATM	Phase Ib study of ART0380 plus low-dose irinotecan in patients with ATM-null metastatic pancreatic cancer that has progressed on one prior line of therapy	Kim Reiss

Metastatic Maintenance
Trial Number	Intervention	Type of Therapy	Description	PI/Contact
S2001	PARP Inhibitor Pembrolizumab	1^st Line – Metastatic Maintenance	A randomized phase II clinical trial of olaparib + pembrolizumab vs. olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 mutations that have not progressed on platinum-based treatment	Kim Reiss
19224 (PARPVAX 2)	Niraparib Ipilimumab FOLFIRI	1^st Line Metastatic Maintenance	PARPVAX 2: A phase II study of maintenance niraparib plus ipilimumab in patients with metastatic pancreatic cancer whose disease has not progressed on platinum-based therapy	Kim Reiss
UPCC 22924 (MOMA)	MOMA-313, Olaparib	2^nd Line Maintenance Metastatic BRCA/PALB2	A Phase 1 study of MOMA-313 given as monotherapy or in combination with a PARP inhibitor in participants with sdvanced or metastatic solid tumors	Kim Reiss

Biomarker Trials
Trial Number	Intervention	Type of Therapy	Description	PI/Contact
UPCC 16224	Pancreatic Tissue Acquisition	No Therapy	Protocol to permit the acquisition of samples of tumor and normal tissue for biological endpoints in pancreatic cancer	Kim Reiss, Ben Stanger, Sean O’Connor
UPCC 02215	Circulating Tumor Material	No Therapy	Protocol to permit the acquisition of circulating tumor material in pancreatic diseases and control subjects	Peter O’Dwyer

Please contact your Abramson Cancer Center Oncologist about enrollment into a trial. If you do not have an Abramson Cancer Center Oncologist, please contact our Pancreas Nurse Navigator Patricia Gambino at 215-615-0537 or patricia.gambino@pennmedicine.upenn.edu to make an appointment with one to discuss clinical trials.

Please note that openings for clinical trials are highly variable. Consequently, at any given time there may not be open slots for the trials shown here. Conversely, slots may be available for clinical trials that have not yet been listed on this page. To determine whether a clinical trial may be appropriate for you, please contact your Abramson Cancer Center Oncologist at 1-800-789-7366.